Table 2.
Examples of peptides in different clinical trials and their indications
| Clinical trial phase | Peptide name | Indication(s) for investigation |
|---|---|---|
| IV | Avexitide500 | Hypoglycemia |
| Calcitonin gene-related peptide501 | Migraine | |
| Corticorelin502 | Brain swelling; brain neoplasms | |
| Leptin503 | Lipodystrophy; obesity | |
| Thymalfasin504 | Liver Cirrhosis; Sepsis | |
| III | Aclerastide505,506 | Diabetic foot ulcers |
| Albusomatropin507 | Growth hormone deficiency | |
| Anamorelin508 | Cachexia; lung cancer non-small cell cancer | |
| G17DT509 | Various forms of cancer | |
| Insulin peglispro510 | Diabetes mellitus | |
| Lenomorelin511 | Malignancies | |
| Selepressin512 | Shock; septic | |
| Somapacitan513 | Adult growth hormone deficiency | |
| Taspoglutide514 | Type 2 diabetes mellitus | |
| Thymosin beta-4515 | Dry eye syndrome | |
| Tirzepatide516 | Type 2 diabetes mellitus | |
| Ularitide517 | Decompensated heart failure | |
| Vapreotide518 | Gastric varices; oesophageal haemorrhage; portal hypertension; esophageal varices | |
| Vosoritide519 | Achondroplasia | |
| Zoptarelin doxorubicin520 | Endometrial cancer; prostate cancer | |
| II | Angiotensin 1-7521 | Miscellaneous Peripheral Blood Cell Abnormalities |
| Bombesin522 | Prostate cancer | |
| Cenderitide310 | Heart failure | |
| Deslorelin523 | Puberty; precocious | |
| Gastric inhibitory polypeptide524 | Type 2 diabetes mellitus | |
| MK-3207525 | Migraine | |
| Olcegepant526 | Migraine Disorders | |
| Pancreatic Polypeptide527 | Type 1 diabetes | |
| Peptide YY (3-36)528 | Metabolic disease; obesity | |
| Pirnabine529 | Chronic idiopathic constipation | |
| Somatoprim530 | Acromegaly | |
| Somatropin pegol531 | Growth hormone deficiency | |
| Thyrotropin532 | Benign nontoxic and toxic goiter; goiter; nodular | |
| TT-232533 | Renal cell adenocarcinoma | |
| I | BPI-3016534 | Type 2 diabetes mellitus |
| NBI-6024535 | Type 1 diabetes mellitus | |
| Many more… |